Zacks.com on MSN4h
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
CRISPR Therapeutics AG (CRSP) closed at $39.41 in the latest trading session, marking a -0.76% move from the prior day.
Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move
Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...
Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)
Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...
Truist Financial Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)
Truist Financial analyst Joon Lee maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today. The company’s shares closed ...
Nasdaq3d
CRISPR Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?
CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks Consensus Estimate for quarterly sales is pegged at $10.13 million ...
Crispr Therapeutics management to meet with Truist
Group Dinner Meeting to be held in New York on February 5 at 6 pm hosted by Truist. Maximize Your Portfolio with Data Driven Insights:Leverage ...
ETF Daily News4d
What is HC Wainwright’s Forecast for CRSP FY2024 Earnings?
CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) – Stock analysts at HC Wainwright issued their FY2024 EPS estimates for shares of CRISPR Therapeutics in a report released on Monday ...
STAT4d
The CRISPR companies are not OK
Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...
ETF Daily News6d
CRISPR Therapeutics AG (NASDAQ:CRSP) Sees Significant Increase in Short Interest
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) saw a large growth in short interest during the month of January.As of January 15th, there was short interest totalling 19,100,000 shares ...